Interplay of transcription factors STAT3, STAT1 and AP-1 mediates activity of the matrix metallo-proteinase-1 promoter in colorectal carcinoma cells.


Journal

Neoplasma
ISSN: 0028-2685
Titre abrégé: Neoplasma
Pays: Slovakia
ID NLM: 0377266

Informations de publication

Date de publication:
23 May 2019
Historique:
received: 31 07 2018
accepted: 06 11 2018
pubmed: 21 12 2018
medline: 10 9 2019
entrez: 21 12 2018
Statut: ppublish

Résumé

Signal Transducers (STATs) 1 and 3 and Activator Protein 1 (AP-1) are transcription factors involved in the development of malignancy in colorectal carcinoma (CRC). Matrix Metalloproteinase 1 (MMP-1) is a protease frequently dysregulated in de-differentiated and invasive cancer cells. Its expression is influenced by STAT and AP-1 transcription factors. We studied their contributions to transcriptional regulation of MMP-1 in colorectal carcinoma (CRC) cells. Both STAT3 and AP-1 contribute individual expression-inducing and additive effects and interact with the MMP-1 promoter. DNA binding of AP-1 protein c-Jun is stimulation-independent but modulated by STAT3 and a STAT recognition DNA element. Activated STAT3 showed a suppressive effect on AP-1-mediated MMP-1 mRNA upregulation as shown by STAT3 knockdown. Surprisingly, activated STAT1 overcame STAT3-dependent repression of AP-1-driven MMP-1 expression. Moreover, combined STAT3, STAT1 and AP-1 activities evoked maximal MMP-1 mRNA levels in a synergistic manner. Our results suggest a dominant role of AP-1 in transcriptional upregulation of MMP-1 in CRC cells which is modulated by joint functions of STAT3 and STAT1. The individual and combinatorial activity of these factors is of diagnostic and prognostic interest.

Identifiants

pubmed: 30569725
doi: 10.4149/neo_2018_180731N560
pii: 180731N560
doi:
pii:

Substances chimiques

STAT1 Transcription Factor 0
STAT1 protein, human 0
STAT3 Transcription Factor 0
STAT3 protein, human 0
Transcription Factor AP-1 0
Matrix Metalloproteinase 1 EC 3.4.24.7

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

357-366

Auteurs

A Muller (A)

Institute of Biochemistry II, University Hospital Jena, Jena, Germany.
Clinic and Polyclinic of Neurology, University Hospital Leipzig, Leipzig, Germany.

J Gasch (J)

Institute of Biochemistry II, University Hospital Jena, Jena, Germany.
Helios-Klinikum Erfurt, Erfurt, Germany.

K F Albring (KF)

Institute of Biochemistry II, University Hospital Jena, Jena, Germany.
Carl-von-Ossietzky-Gymnasium, Berlin, Germany.

F Aberger (F)

Department of Molecular Biology, University of Salzburg, Salzburg, Austria.

H Nivarthi (H)

Ludwig Boltzmann Institute for Cancer research, Medical University of Vienna, Vienna, Austria.
Research Center for Molecular Medicine , Austrian Academy of Sciences, Vienna, Germany.

M Khemeri (M)

IMEC, Faculty of Sciences of Bizerte, Bizerte, Zarzouna, Tunisia.

R Moriggl (R)

Ludwig Boltzmann Institute for Cancer research, Medical University of Vienna, Vienna, Austria.

K H Friedrich (KH)

Institute of Biochemistry II, University Hospital Jena, Jena, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH